nadp has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, M; Arnason, J; Avigan, D; Bar-Natan, M; Bhargava, P; Clark, RA; Coll, MD; Jain, S; Joyce, R; Kufe, D; Kupper, TS; Luptakova, K; Palmer, K; Pyzer, A; Rajabi, H; Rosenblatt, J; Stroopinsky, D; Yin, L | 1 |
1 other study(ies) available for nadp and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Case-Control Studies; Cell Proliferation; Female; Flow Cytometry; Glutathione; Humans; Immunoenzyme Techniques; Intracellular Signaling Peptides and Proteins; Lymphoma, T-Cell, Cutaneous; Mice; Mice, Inbred NOD; Mice, SCID; Mucin-1; NADP; Necrosis; Oxidative Stress; Peptides; Phosphoric Monoester Hydrolases; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Skin Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |